138 filings
Page 6 of 7
6-K
kqedxloe44ogtkl624fu
26 Feb 21
Current report (foreign)
8:28am
D
p3f78 q5y0gd61
18 Feb 21
$45.5M in equity, sold $45.5M, 12 investors
11:18am
SC 13G
jbhcep50oqa fil726u
17 Feb 21
Silence Therapeutics / Keith Robert Napier ownership change
3:53pm
SC 13G
xtfhlqobxlt7lemrp72u
17 Feb 21
Silence Therapeutics / Griffiths Richard Ian ownership change
3:47pm
SC 13G
kes9puql
17 Feb 21
Silence Therapeutics / Quested Robert ownership change
3:46pm
6-K
xzyq7o9ip jpgf0
17 Feb 21
Current report (foreign)
8:51am
SC 13G
d99vef31m700duqbuu
16 Feb 21
Silence Therapeutics / Lombard Odier Asset Management ownership change
12:00am
6-K
2sq8cr 7lzt
5 Feb 21
Securities Purchase Agreement
9:40pm
6-K
mzrez2iu dtztu
6 Jan 21
Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer
7:33am
6-K
e8c5za48
16 Nov 20
Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020
7:00am
6-K
6breb wnw1n8aom
2 Nov 20
Silence Therapeutics Appoints Dr. Marie Wikström Lindholm to its
7:31am
6-K
2sim1s5pv hz2wm4cg
8 Oct 20
Silence Therapeutics Announces Change to Executive Leadership Team
7:35am
EFFECT
j38zwtu sg1i0m8
5 Oct 20
Notice of effectiveness
12:20am
POS AM
svp5aqptv m20fy7g
23 Sep 20
Prospectus update (post-effective amendment)
4:47pm
6-K
k25at0yzx8
14 Sep 20
Silence Therapeutics Appoints Mark Rothera as President and Chief Executive Officer
7:10am
S-8
iiyc9z kfz
9 Sep 20
Registration of securities for employees
2:36pm
6-K
za1vbc
8 Sep 20
Silence Therapeutics Provides Research and Development Update
7:35am
424B4
i7s19ynclsr6l1 ezx
8 Sep 20
Prospectus supplement with pricing info
7:31am
EFFECT
w0udlul
8 Sep 20
Notice of effectiveness
12:15am
CERT
wjv07t
8 Sep 20
Certification of approval for exchange listing
12:00am